Market immunity? How public safety warnings have little impact on drug sales volumes or company share prices
- Written by Jeremy Edmund Clark, Associate Professor, Department of Economics and Finance, Business School, University of Canterbury
ShutterstockThe race by pharmaceutical companies to find effective vaccines for COVID-19 has shone a global spotlight on the trade-offs regulators face in approving new drugs.
Under the system used by drug regulators in the US, Europe and elsewhere, drug companies need only show from clinical trials that new drugs have short-term safety and...
